Today, Eli Lilly had good news to share about the performance on its oncology drug, ramucirumab, for the treatment of non-small cell lung cancer. In ths study, the mAb was combined with chemotherapy and docetaxel. The positive results ae welcme news for Lilly as the company has been plagued by a string of late stage failures over the past several years -- at a time where it is also bleeding revenues from drugs coming off patent. Ramucirumab has also had posiive results with gastric cancers. Now we wait on wo aditional studies for liver and colorectal cancers. Those results will dtermine if Lilly has a home run on its hands or not -- analysts estimate peak sales in the $1.5-$2 B range if the drug passes muster. See Fierce Biotech.
Posted by Bruce Lehr Feb 19th 2014.